Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04488458
Other study ID # 2020-01471
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date August 15, 2021
Est. completion date December 31, 2023

Study information

Verified date July 2021
Source Vastra Gotaland Region
Contact Ola Rolfson, Professor
Phone +46 313430852
Email ola.rolfson@vgregion.se
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The overall purpose of this clinical treatment research project is to explore novel diagnostics that can guide the treatment of infections associated to orthopaedic implants, in order to improve patient outcomes and reduce the development of antibiotic resistance. The project aims are: (i) To improve the current diagnostic approaches and treatments of periprosthetic joint infections (PJI) (ii) To investigate the pathogenesis of PJI through the characterization of the virulence carried by the causative pathogens This multidisciplinary project addresses implant-associated infection and its contribution to increasing antibiotic resistance. Both lead to longer hospital stays, higher medical costs and increased morbidity and mortality. Antibiotic resistance is globally considered as one of the greatest and most urgent risk in medicine. Implant-associated infections are commonly caused by biofilms. Biofilms can be described as 'a community of bacterial cells connected by their secreted extracellular matrix'. Since antibiotics are designed to fight planktonic free-living bacteria, studying antibiotic resistance in biofilm communities poses a paradigm shift. Furthermore, bacteria in biofilms are up to 1000 times more resistant to antibiotics than planktonic bacteria. Mechanisms involved in a biofilm infection also play a crucial role in the development of antibiotic resistance. Hospital-acquired infections are the fourth leading cause of disease and 70% are associated with medical implants and caused by staphylococcal biofilms. In addition, the level of antimicrobial resistance in bacteria causing implant-associated infections has increased worldwide, leaving patients with fewer treatment options. In this study the investigators will randomize patients with PJI to either standard MIC susceptibility or MIC and MBEC susceptibility guided treatment with oral antibiotic combinations; (i) Non cell wall active standard of care antibiotic combination (MIC-guided) for 6 weeks. (ii) Or; non cell wall active antibiotic combination according to a MBEC-based decision algorithm for 6 weeks. In this pilot project, the primary endpoint is how often treatment changes with the MBEC susceptibility testing compared to only MIC-susceptibility testing.


Description:

In the infectious process, biofilms may form early on biomaterials. There is ample evidence to the several-fold increase in antimicrobial concentrations required to eradicate even immature biofilms. In clinical practice the choice of antimicrobials is guided by susceptibility testing based on minimum inhibitory concentrations (MIC), which poorly reflect the increased antimicrobial resistance in biofilms. Minimum biofilm eradicating concentrations (MBEC) might better correspond to in vivo efficacy in the treatment of PJI, and other biofilm-centred infections. There is a need to develop methods, which are reproducible, low-cost, and time-efficient, for in vitro susceptibility testing of clinical biofilm bacteria. This prospective randomized study aim to compare antibiotic treatment regimens for PJI guided by MIC or MBEC combined with MIC, and how it affects infection resolution, drug tolerability and relapse strain resistance patterns. The investigors hypothesize that a standardised surgical debridement, antibiotics and implant retention (DAIR) for PJI followed by antibiotic guiding MBEC-diagnostics on deep tissue specimens will increase treatment efficacy and decrease the incidence of infection relapses compared to standard of care. Following standardised debridement and 14 days of parenteral antibiotics; cloxacillin for methicillin sensitive staphylococci or vancomycin for methicillin resistant staphylococci, patients will be randomized to receive oral antibiotic combinations with either cell wall active standard of care antibiotic combination (MIC-guided) for 6 weeks or non cell wall active antibiotic combination according to a MIC- and MBEC-guided decision algorithm for 6 weeks. Patients will be included at the Orthopaedic Infection Centre (OIC), Sahlgrenska University Hospital/Mölndal, which is a unit dedicated to optimizing management of orthopaedic infections. Patient consent acquisitions and randomisations (20 patients in each group) will be performed during post-operative hospitalisation. MIC determination and disk diffusion will be performed at the SWEDAC (Swedish Accreditation Body) certified clinical bacteriological laboratory. At the department of Biomaterials (University of Gothenburg), a previously developed clinical diagnostic tool will be employed for the MBEC determination. It consists of the combination of the Calgary Biofilm Device (MBECTM P&G Assay, Innovotech) and a custom-made susceptibility plate (Substrata department, Sahlgrenska Hospital) with 6 antimicrobial agents commonly used to treat orthopaedic infections. Inclusion and exclusion criteria are described in section "Eligibility". The primary and secondary endpoints are described in section "Outcome measures". Treatment criteria: for all administered antimicrobials staphylococcal strains must be susceptible in disc diffusion tests/MIC, regardless of MBEC-level. Antibiotic combinations will be selected from 5 already recommended non-cell wall active anti-staphylococcal antibiotics with high per-oral bio-availabilities and acceptable bone penetration used in the treatment of PJIs: rifampicin (RIF), fusidic acid (FUS), ciprofloxacin (CIP)/levofloxacin (LEV) and clindamycin (CLI). Clinical breakpoints are expressed as MIC (EUCAST and CLSI) but are based on more than MIC distributions (epidemiological cut-off) namely: - Pharmacokinetic and pharmacodynamic analyses of the antibiotic. - Relation between MIC and probability of cure in clinical trials. If likely effective according to EUCAST clinical breakpoints, antibiotics are further ranked in the MBEC treatment algorithm by bone penetration/susceptibility range and semi-arbitrarily by clinical efficacy in prosthetic joint infections. MBEC/MIC cut-off for replacing Rifampicin despite susceptibility according to MIC: - C-Max (oral dose of 750 mg) 10 mg/L x 0.4 (Bone/Serum) = 4 mg/L - RIF-MIC clinical breakpoint for staphylococci is 0.5 mg/L. - Clinical efficacy factor 1. - MBEC/MIC ≥ 8 times MIC. MBEC/MIC cut-off for replacing Levofloxacin despite susceptibility according to MIC: - C-Max (oral dose of 750 mg) 12 mg/L x 0.6 (Bone/Serum) = 7,2 mg/L - LEV-MIC breakpoint for staphylococci is 1 mg/L - Clinical efficacy factor 0,75. - MBEC/MIC ≥ 5 x MIC. MBEC/MIC cut-off for not choosing Fusidic acid as companion drug: - C-Max (500 mg) 30 mg/L x 0,2 (Bone/Serum) = 6 mg/L - FUS-MIC breakpoint for staphylococci is 1 mg/L. - Clinical efficacy factor 0,5. - MBEC 3 times the MIC or more if better companion drug. MBEC/MIC cut-off for not choosing Clindamycin as companion drug: - C-Max (600 mg) 12 mg/L x 0.3 (Bone/Serum) = 3,6 mg/L - CLI-MIC breakpoint for staphylococci is 0.5 mg/L - Clinical efficacy factor 0,5. - MBEC/MIC 4 x MIC or more if better companion drug. MBEC/MIC cut-off for not choosing Linezolid (LIN) as sole drug: - C-Max 21 mg/L x 0.4 (Bone/Serum) = 8,4 mg/L - LIN-MIC breakpoint for staphylococci is 4 mg/L - Clinical efficacy factor 0,5. - MBEC 2 times the MIC or more. MBEC cut-off for not choosing Sulfamethoxazole (SMX)/Trimethoprim (TMP) as sole drug: - C-Max (3200/640 mg SMX/TMP) is 145 and 7.5 mg/L resp. x 0.25 (Bone/Serum) = 36 and 1,9 mg/L resp. - SMX/TMP-MIC breakpoint for staphylococci is 2 mg/L. (By EUCAST expressed as the Trimethoprim konc.) - Clinical efficacy factor 0,5. - MBEC > MIC - *Interpret as better than according to justification above. All follow-up up to one year will be done according to clinical routines.


Recruitment information / eligibility

Status Recruiting
Enrollment 40
Est. completion date December 31, 2023
Est. primary completion date December 31, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - first PJI in hip or knee according to Musculoskeletal Infection Society (MSIS) definitions - first DAIR - mono-microbial staphylococcal infection - 14 days of intravenous treatment with either cloxacillin or vancomycin - standardized administration of local antibiotics Exclusion Criteria: - allergy/previous toxic event/unacceptable drug interaction to most effective antibiotic combination according to either MIC or MBEC - severe drug interactions to MBEC-guided compound

Study Design


Intervention

Diagnostic Test:
MIC or MBEC+MIC based treatment algorithm
i) Non cell wall active standard of care antibiotic combination (MIC-guided) for 6 weeks. ii) Non cell wall active antibiotic combination according to a MBEC-based decision algorithm for 6 weeks.

Locations

Country Name City State
Sweden Ortopedi, Sahlgrenska University Hospital Mölndal

Sponsors (2)

Lead Sponsor Collaborator
Vastra Gotaland Region Göteborg University

Country where clinical trial is conducted

Sweden, 

References & Publications (1)

Zaborowska M, Tillander J, Brånemark R, Hagberg L, Thomsen P, Trobos M. Biofilm formation and antimicrobial susceptibility of staphylococci and enterococci from osteomyelitis associated with percutaneous orthopaedic implants. J Biomed Mater Res B Appl Biomater. 2017 Nov;105(8):2630-2640. doi: 10.1002/jbm.b.33803. Epub 2016 Oct 25. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Other Correlation between the virulence properties of the causative bacteria and patient outcome (infection resolution versus recurrent infection) The staphylococcal strains isolated from the patients with PJI will be characterised by phenotypic tests and whole genome sequencing to determine their virulence properties and carriage of genes involved in biofilm formation, antimicrobial resistance and production of toxins. Then the particular virulence of the strains will be correlated to the patients outcome, to be able to assess if more virulence carriage correlates to worse outcome (recurrent infection) 36 months
Primary Number of changes in antimicrobial regimen other than standard of care Proportions of antimicrobial regimens other than standard of care through application of proposed MBEC-algorithm. 6 weeks
Secondary Repeat procedure, relapse or reinfection Number of repeat procedures, relapses or reinfections, according to MSIS-criteria of PJI 12 months
Secondary Oxford Hip Score Hip specific patient-reported outcome measure 12 months
Secondary EQ-5D Generic health status patient-reported outcome measure 12 months
Secondary Time to revision A shorter time could potentially indicate that the right decision is taken at an earlier stage 12 months
Secondary Inpatient care Resource consumption measure (days). Up to 12 months
Secondary Outpatient visits Resource consumption measure, number of visits, type of visits. Up to 12 months
Secondary Discharge destination Resource consumption measure. The type of facility a patient is discharged to (rehab facility, nursing home, home, home care). Up to 12 months
Secondary Heath care costs Compound measure using data from outcome 6-8 (currency EUR). Up to 12 months
Secondary Development of additional antimicrobial resistance of the relapse causative strain At relapse surgery, the causative strain will be isolated by new biopsy cultures. Then the susceptibility of the causative strain will be tested again to evaluate any possible emergence of resistance against the antimicrobials previously used in the study. This will confirm if the given antimicrobial treatment has lead to antimicrobial resistance in a potential relapse strain isolated at a later occasion. 12 months
See also
  Status Clinical Trial Phase
Completed NCT04067843 - Effect of Photodynamic Treatment on Skin Microbiome. Single Center Study N/A
Enrolling by invitation NCT05247281 - NGS vs Culture Outcomes for Treatment of PJI N/A
Withdrawn NCT05269121 - Bacteriophage Therapy in First Time Chronic Prosthetic Joint Infections Phase 1/Phase 2
Recruiting NCT02801253 - Cohort of Prosthetic Joint Infections
Completed NCT03694925 - Diagnostic Utility of a Novel Point-of-Care Test of Calprotectin for Revision Total Knee Arthroplasty
Completed NCT03721328 - Safety and Efficacy in Patients Treated for Hip or Knee PJI With Vancomycin and Tobramycin Joint Irrigation Phase 2
Withdrawn NCT04787250 - Bacteriophage Therapy in Patients With Prosthetic Joint Infections Phase 1/Phase 2
Recruiting NCT03307109 - Quality of Life in Patients Having a Prosthetic Joint Infection
Recruiting NCT04661345 - Identification of Molecular Marker of Coagulase-negative Staphylococci for the Diagnosis of Prosthetic Joint Infections
Recruiting NCT02805803 - Quality of Life Assessment in Patients Undergoing Prolonged Suppressive Antibiotherapy for Prosthetic Joint Infection. N/A
Completed NCT02413034 - The Influence of Antibiotic Prophylaxis on Intraoperative Prosthetic Joint Infection Cultures N/A
Recruiting NCT03784807 - New Strategies for Biofilm Related Infections
Completed NCT04662632 - Abbreviated Protocol for Two-Stage Exchange Phase 2
Not yet recruiting NCT04390607 - Leukocyte Esterase Sensor Test
Recruiting NCT04650607 - Phage Safety Cohort Study
Active, not recruiting NCT04946500 - Clindamycin in Prosthetic Joint Infections Caused by Staphylococcus (CISTA)
Recruiting NCT04762706 - Measuring Distress in Prosthetic Joint Infection Using a Standardized Metric: CRUTCH Pathway Pilot. N/A
Withdrawn NCT05269134 - Bacteriophage Therapy in Patients With Prosthetic Joint Infections (PJI) Phase 2
Not yet recruiting NCT05239312 - Antibiogram and Biofilm Formation of Bacteria Causing Prosthetic Joint Infections Isolated From Assiut University Hospital
Completed NCT04294862 - Tissue Distribution, Pharmacokinetics, Safety, and Tolerability After a Single Dose of TNP-2092 in Participants Undergoing Primary Total Hip or Knee Arthroplasty Phase 1